U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06908304) titled 'A Phase Three Study with THIO + Cemiplimab Vs Chemo As 3L Treatment in Advanced/metastatic NSCLC' on March 20.
Brief Summary: THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO(R)). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death.
Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with...